Recombinant FVIIa: all 59 studies that test it

Page 1 of 1. Open to participants first (4), then studies with results posted, then the rest; newest registration first within each.

• Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2RecruitingNCT07227246Phase 3
• A Research Study to See How Safe is Eptacog Alfa When Used to Stop Heavy Bleeding in Women After Giving Birth in IndiaRecruitingNCT07157423Phase 4
• Eptacog Beta in Glanzmann's (HeT_LFB-Strength-Study_FID531)RecruitingNCT07136857Phase 2
• SEVENFACT® for Bleeding Events in Hemophilia With InhibitorsRecruitingNCT04647227Phase 4
• Safety and Efficacy of FVIIa to Prevent Excessive Bleeding in Hemophilia Patients With Inhibitors Undergoing Major SurgeryTerminatedNCT05695391Phase 3Results posted
• LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive ProceduresCompletedNCT02548143Phase 3Results posted
• Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With InhibitorsCompletedNCT02020369Phase 3Results posted
• Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and InhibitorsCompletedNCT01392547Phase 3Results posted
• The Spot Sign for Predicting and Treating ICH Growth StudyCompletedNCT00810888Phase 2Results posted
• Haemophilia Patients With Inhibitors Being Treated for Acute Joint BleedsCompletedNCT00486278Phase 2Results posted
• Effect of rFVIIa on Peri-operative Blood Loss in Patients Undergoing Major BurnCompletedNCT00243243Phase 3Results posted
• Evaluation of Recombinant Factor VIIa in Patients With Severe BleedingTerminatedNCT00184548Phase 3Results posted
• A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy ParticipantsCompletedNCT04543383Phase 1
• Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke TrialActive, not recruitingNCT03496883Phase 3
• Study Comparing the Pharmacokinetic of Biosimilar Eptacog Alfa With Novoseven®, in Patients With Congenital Factor VII DeficiencyCompletedNCT03079063Phase 3
• Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven® in Healthy Male SubjectsWithdrawnNCT02084810Phase 1
• A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B With or Without InhibitorsCompletedNCT01949792Phase 1
• A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or BCompletedNCT01708564Phase 1
• Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic FeverCompletedNCT01601613Phase 2
• Activated Recombinant Human Factor VII in Pelvic-acetabular Fracture ReconstructionCompletedNCT01601457Phase 2
• Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII in Acute Intracerebral HaemorrhageCompletedNCT01566786Phase 2
• Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell TransplantationTerminatedNCT01564563Phase 2
• Efficacy and Safety of Activated Recombinant Human Factor VII in Severely Injured Trauma PatientsCompletedNCT01563523Phase 2
• Safety and Tolerability of Intravenous Doses of Activated Recombinant Human Factor VII in Healthy VolunteersCompletedNCT01563471Phase 1
• Safety and Efficacy of Activated Recombinant Human Factor VII in Patients Undergoing Orthotopic Liver TransplantationCompletedNCT01563458Phase 2
• Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral HaemorrhageCompletedNCT01563445Phase 2
• Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial HepatectomyCompletedNCT01562821Phase 2
• Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding StateCompletedNCT01562587Phase 1
• Activated Recombinant Human Factor VII Following Cardiac Bypass Surgery for Paediatric Congenital Heart DiseaseCompletedNCT01562574Phase 3
• Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding StateCompletedNCT01562457Phase 1
• Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell TransplantationCompletedNCT01562158Phase 2
• Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated BleedingTerminatedNCT01561950Phase 1
• Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin TreatmentCompletedNCT01561937Phase 1
• Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of ThromboelastographyCompletedNCT01561924Phase 1
• Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male SubjectsCompletedNCT01561417Phase 1
• Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major SurgeryCompletedNCT01561391Phase 4
• Efficacy and Safety of Activated Recombinant Human Factor VII in Refractory Haemorrhagic CystitisCompletedNCT01561352Phase 2
• A Single and Low Dose of Recombinant Factor VIIa in Patients With Severe Factor XI Deficiency Undergoing SurgeryStatus unknownNCT01538160Not applicable
• "Spot Sign" Selection of Intracerebral Hemorrhage to Guide Hemostatic TherapyCompletedNCT01359202Phase 2
• rFVIIa Prophylaxis in Children With Hemophilia A and InhibitorsStatus unknownNCT01105546Phase 2
• Factor VII, Prothrombin Complex Concentrate, and Fresh Frozen Plasma in Warfarin-Related Intracranial HemorrhageTerminatedNCT00770718Phase 1
• High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With InhibitorsCompletedNCT00571584Phase 4
• Recombinant Factor VIIa in Acute Intracerebral HaemorrhageCompletedNCT00426803Phase 2
• Recombinant Factor VIIa (NovoSeven) on Restoring Coagulation ActivationCompletedNCT00375323Phase 3
• rhuFVIIa in Post-partum HemorrhageCompletedNCT00370877Phase 4
• Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to TraumaWithdrawnNCT00323570Phase 3
• Combination Therapy of Low Doses of rFVIIa and FEIBA for Severe Hemophilia A Patients With an Inhibitor to Factor VIIICompletedNCT00284193Phase 4
• Factor VIIa in Acute Intracerebral HaemorrhageCompletedNCT00266006Phase 2
• rFVIIa in ICH in Patients Treated With Anticoagulants or Anti-PlateletsStatus unknownNCT00222625Phase 2
• "Salvage Use" of Recombinant Factor VIIa After Inadequate Haemostasis in Complex Cardiac SurgeryStatus unknownNCT00214656Phase 3
• The FEIBA NovoSeven Comparative StudyCompletedNCT00166309Not applicable
• Use of NovoSeven® in Active Variceal BleedingCompletedNCT00154492Phase 2
• Use of Activated Recombinant Human Factor VII in Cardiac SurgeryTerminatedNCT00154427Phase 2
• Efficacy and Safety of Factor VIIa on Rebleeding After Surgery for Spontaneous Intracerebral Hemorrhage (ICH)CompletedNCT00128050Phase 2
• Recombinant Factor VIIa in Acute Intracerebral HaemorrhageCompletedNCT00127283Phase 3
• Safety and Preliminary Efficacy of Recombinant Activated Factor VII in Subjects With Traumatic Brain InjuryCompletedNCT00123591Phase 2
• Efficacy of NovoSeven® in Bleeding Prophylaxis in HemophiliaCompletedNCT00108758Phase 2
• Dose Response to Recombinant Factor VIIa When Administered for BleedCompletedNCT00104455Phase 1
• Use of Activated Recombinant FVII in Spinal SurgeryCompletedNCT00102037Phase 2

← Recombinant FVIIa overview